
Leveraging team science to exploit the tumour’s ‘Achilles heel’ with PARP inhibition: a journey of discovery and perseverance
Extensive research identified the deficiency of a highly accurate DNA repair process known as homologous recombination as an ‘Achilles heel’ in cancer, and led to the development of PARP inhibitors as single-agent therapies

Choose the right treatment, at the right dose – a way to create a financially-sustainable cancer care?
Using treatments only where clear benefit has been demonstrated and modulating doses based on evidence are potentially effective strategies to reduce the rising costs of oncology

Do young patients benefit from immune checkpoint inhibitors?
First evidence for the efficacy of anti-PD-1 agents in children, adolescents and young adults with melanoma prompts the call for a change in cancer care for this population

Doublet immunotherapy consolidates its role in hepatocellular carcinoma
Benefits reported for the combination of ipilimumab and nivolumab further expand alternative therapeutic options for patients with unresected advanced disease

Ten years of improvement in the treatment of liver cancer
Novel agents, a rethinking of accepted treatment concepts and new roles for older treatment modalities are now driving liver cancer management

Harnessing the power of the gut microbiome in colorectal cancer
Lessons learned about the importance of the gut microbiome composition in immune checkpoint inhibitor therapy response could be crucial in tailoring cancer care

Overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Recent data indicate a role of immunotherapy for tumours with high levels of microsatellite instability, especially in the neoadjuvant setting

Targeting KRAS offers new hope for patients with gastrointestinal cancers
The development of KRAS selective inhibitors promises to expand treatment to a broader population of patients with KRAS-mutated tumours

Towards a brighter future for gynaecological cancers
Improvements in the understanding of molecular mechanisms, together with a greater focus on prevention, are key elements to countering gynaecological malignancies

New insights into the evolutionary pattern of breast cancer
A more detailed picture of breast cancer establishment may facilitate prevention and detection in women at high risk